InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 15 August 2023

This phase I trial is evaluating an intravenous drug (BFCR4350A) in patients with multiple myeloma, who have progressed or not responded to prior treatmentAn Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BFCR4350A in Patients With Relapsed or Refractory Multiple Myeloma

Clinical summary


Dose escalation: The study drug will be administered intravenously on a 21-day cycle. Initially, cohorts will consist of 1 participant each. Subsequently will consist of at least 3 participants, unless dose-limiting toxicities (DLTs) are observed in the first 2 prior to enrollment of a third participant. For each cohort, treatment with the first dose will be staggered such that the second participant enrolled in the cohort will receive study drug at least 72 hours after the first participant receives it to allow assessment of any severe and unexpected acute or subacute drug or infusion-related toxicities; dosing in subsequent participants in each cohort will be staggered by at least 24 hours. Expansion: Participants exhibiting acceptable safety and evidence of clinical benefit will be administered study drug every 21 days up to a maximum of 17 cycles until objective disease progression is documented or unacceptable toxicity, whichever occurs first.


This trial is treating patients with Multiple Myeloma.


Blood Cancers Blood





More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Commercial Sponsor


Scientific Title

An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BFCR4350A in Patients With Relapsed or Refractory Multiple Myeloma



  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.


  • You have certain types of non-cancer medical conditions.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

+ Show non-recruiting hospitals

Closed hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support


Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more


Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more


Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.


Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.